MedTrace Logo

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

NCT05956821 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-08

No results posted yet for this study

Summary

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.

Conditions

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Fibrillary Astrocytomas
  • Oligodendroglioma
  • Diffuse Intrinsic Brainstem Glioma
  • Diffuse Intrinsic Pontine Glioma
  • DIPG Brain Tumor
  • H3 K27M

Interventions

DRUG

SIACI of cetuximab and bevacizumab

Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Heather McCrea, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-19
Primary Completion
2029-10-01
Completion
2029-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05956821 on ClinicalTrials.gov